Abstract:Inhibitors of DNA methyltransferase (DNMTs) are now a major family of epigenetic targets with therapeutic interest. However, only two cytosine analogues 5-azacytosine (azacytidine) and 20-deoxy-5-azacytidine (decitabine), have been approved as the most cutting-edge medications for treating epigenetic cancer with some restrictions. In this context, computational methods that rely on quantitative structure-activity relationship (QSAR) play a crucial role allowing us to predict the biological activity of potential molecules based on the theoretically calculated physicochemical properties of these compounds. When coupled with machine learning (ML), QSAR approaches create an ideal platform for discovering potential drug candidates. In this study, three Machine Learning (ML) models; Random Forest, Support Vector Machine, and Artificial Neural Network, were trained using modified TeachOpenCADD KNIME workflows and applied it to the identification of plant molecules that are structurally similar to the active pharmaceuticals of current DNMT inhibitors. Then molecular docking simulations were performed using AutoDock Vina, employing two human DNMT structures (PDB codes: 4WXX and 2QRV) as target proteins and the predicted phytochemicals as ligands. Additionally, we focused on the R882H mutation hotspot in the catalytic domain of DNMT3A, which is associated with aberrant DNA methylation in acute myeloid leukemia (AML). Consequently, the structure of R882H DNMT3A (PDB code: 6W8J) was docked with the identified novel ligands. As a result of our computational analysis, eight phytochemicals were predicted as potential DNMT inhibitors through the ML approaches from KNIME. Subsequently, three of these phytochemicals, namely Herbacetin, Kaempferide, and Morin were identified as virtual hits against DNMTs following the molecular docking simulations. Overall, our study demonstrates the effectiveness of this computational strategy in identifying DNMT inhibitors. These findings hold promise for the discovery of potent and selective anticancer drugs targeting DNMTs.

Fragment-based discovery of new potential DNMT1 inhibitors integrating multiple pharmacophore modeling, 3D-QSAR, virtual screening, molecular docking, ADME, and molecular dynamics simulation approaches

Identifying Novel Selective Non-Nucleoside DNA Methyltransferase 1 Inhibitors Through Docking-Based Virtual Screening.

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

Supercomputer-Based Virtual Screening for Deoxyribonucleic Acid Methyltransferase 1 Inhibitors as Novel Anticancer Agents

Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy

Insight into the Selective Binding Mechanism of DNMT1 and DNMT3A Inhibitors: a Molecular Simulation Study.

Integrated Virtual Screening and Molecular Dynamics Simulation Approaches Revealed Potential Natural Inhibitors for DNMT1 As Therapeutic Solution for Triple Negative Breast Cancer.

Computer-aided drug design to discover DNMT inhibitors from phytochemicals

A Computational Approach for the Discovery of Novel DNA Methyltransferase Inhibitors

Exploration of Novel MTH1 Inhibitors Using Fragment-Based De Novo Design, Virtual Screening, and Reverse Virtual Screening Methods

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

Identification of 3-(9 H -carbazol-9-yl)-2-(1,3-dioxoisoindolin-2-yl)propanoic acids as promising DNMT1 inhibitors

Combined Multi-Pharmacophore, Molecular Docking and Molecular Dynamic Study for Discovery of Promising MTH1 Inhibitors

Do Anticancer Medicinal Compounds have DNMT1 Regulating Activity: An In silico Investigation

DNA Methyltransferase Inhibitors and Their Therapeutic Potential.

DNA Methyltransferase Inhibitors and Their Therapeutic Potential

Targeting DNA methyltransferases for cancer therapy

Natural bioactive compounds targeting DNA methyltransferase enzymes in cancer: Mechanisms insights and efficiencies

DNA methyltransferase inhibitors: an updated patent review (2012-2015)

Identification of potential methyltransferase NSD2 enzymatic inhibitors through a multi-step structure-based drug design

Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors Using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (Sam)-Dependent Methyltransferase Family.